Case Histories of Significant Advances: CAR-T Therapies

24 Pages Posted: 29 Jun 2021 Last revised: 4 Mar 2024

See all articles by Amar Bhide

Amar Bhide

Columbia University - Mailman School of Public Health

Srikant Datar

Harvard University - Accounting & Control Unit

Date Written: May 15, 2021

Abstract

In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers — acute leukemia (ALL) and a lymphoma. We describe: 1) how CAR-T therapies (are believed to) work; 2) foundational advances and discoveries (through the 1980s); 3) the development of CAR-T therapy (during and after the 1990s); and 4) prospects for the 2020s.

Note: Funding Statement: Funding for this research was provided in part by Harvard Business School.

Declaration of Interests: We have no competing interests to report.

Suggested Citation

Bhide, Amar and Datar, Srikant, Case Histories of Significant Advances: CAR-T Therapies (May 15, 2021). Harvard Business School Accounting & Management Unit Working Paper No. 21-035, Harvard Business School General Management Unit Working Paper No. 21-035, Available at SSRN: https://ssrn.com/abstract=3863155 or http://dx.doi.org/10.2139/ssrn.3863155

Amar Bhide (Contact Author)

Columbia University - Mailman School of Public Health ( email )

600 West 168th St., 6th Floor
New York, NY 10032
United States

Srikant Datar

Harvard University - Accounting & Control Unit ( email )

Soldiers Field
Boston, MA 02163
United States
617-495-6543 (Phone)
617-496-7363 (Fax)

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
42
Abstract Views
641
PlumX Metrics